Eli Lilly Acquires Engage Bio for Up to $202M
Eli Lilly has agreed to acquire Engage Biologics, a gene therapy biotech, for up to $202 million. The deal, Lilly's seventh acquisition of 2026, centers on Engage's non-viral DNA delivery platform called Tethosome. This platform enables the delivery of genetic material without using viruses, potentially improving safety and efficacy in gene therapies. The acquisition underscores Lilly's continued investment in genetic medicine.
Key facts
- Eli Lilly is buying Engage Biologics for up to $202 million.
- The deal is Lilly's seventh acquisition of 2026.
- The acquisition centers on Engage's Tethosome platform.
- Tethosome is a non-viral DNA delivery platform.
- Non-viral delivery may improve safety and efficacy in gene therapies.
- The acquisition reflects Lilly's focus on genetic medicine.
Entities
Institutions
- Eli Lilly
- Engage Biologics
Sources
- Quartz —